The advent of CRISPR and genome editing technologies has revolutionized molecular biology, enabling precise modifications in genetic material. A notable study explored the targeting of DCAF5 to suppress SMARCB1-mutant cancers, revealing that the loss of tumor suppressor proteins presents unique vulnerabilities that can be exploited through CRISPR screens (ref: Radko-Juettner doi.org/10.1038/s41586-024-07250-1/). Another significant advancement is the development of high-throughput prime editing sensor libraries, which allow for the evaluation of genetic variants with improved efficiency, addressing previous limitations in prime editing guide RNA effectiveness (ref: Gould doi.org/10.1038/s41587-024-02172-9/). Furthermore, the introduction of near-cognate tRNAs has enhanced the precision of pseudouridine-mediated readthrough of premature termination codons, showcasing the potential of CRISPR technologies in RNA editing (ref: Luo doi.org/10.1038/s41587-024-02165-8/). These studies collectively highlight the versatility and expanding applications of CRISPR technologies in cancer research and genetic engineering, with implications for therapeutic interventions and understanding gene regulation.